EUVIMEDEUVIMED entdecken
Crossref

Fentanyl-xylazine overdose deaths in the USA, 2018–2023

David T Zhu iD, Manuel Cano

Injury Prevention · 2025

DOI: 10.1136/ip-2024-045596 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Injury Prevention, 2025. Verfasst von David T Zhu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Commonwealth University, Richmond, Virginia, USA zhudt@vcu.edu. Hauptthemen laut MEDLINE: Fentanyl, Drug Overdose, Xylazine, Analgesics, Opioid. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Xylazine, a veterinary sedative and analgesic, has emerged as a novel adulterant in the US illicit drug supply, frequently co-occurring with fentanyl. This study examines trends in fentanyl-xylazine overdose death rates from 2018 to 2023.

Methods

This serial cross-sectional study examined death certificates from the CDC WONDER database to identify International Classification of Diseases, 10th Revision codes for overdose deaths likely coinvolving fentanyl (T40.4) and xylazine (T42.7 or T46.5). Crude mortality rates per 100 000 were calculated overall and by sex, race/ethnicity, US Census Divisions and state to examine demographic and geographical trends.

Results

Fentanyl-xylazine deaths increased from 99 in 2018 to 6020 in 2023. Crude mortality rates rose from 0.03 (95% CI 0.02 to 0.04) to 1.80 (95% CI 1.75 to 1.84) per 100 000. In 2023, rates were higher among males than females (2.63 (95% CI 2.55 to 2.71) vs 0.99 (95% CI 0.93 to 1.03) per 100 000), and higher among black than white individuals (3.21 (95% CI 3.04 to 3.38) vs 1.86 (95% CI 1.80 to 1.92) per 100 000). The Middle Atlantic and New England Census Divisions had the highest regional rates at 5.72 (95% CI 5.49 to 5.95) and 4.32 (95% CI 3.99 to 4.65) per 100 000, respectively. Discussion and conclusions The sharp increase in fentanyl-xylazine deaths, particularly among black individuals, highlights both the growing infiltration of xylazine into the illicit drug supply and persistent structural disparities in addiction treatment. Addressing this escalating epidemic requires routine toxicological testing for xylazine and expanded access to trauma-informed care, harm reduction services and interventions such as naloxone, opioid agonist therapies and wound care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FentanylDrug OverdoseXylazineAnalgesics, OpioidHypnotics and SedativesHumansUnited StatesMaleFemaleCross-Sectional StudiesAdultMiddle AgedYoung AdultAdolescent

Stichwörter der Autor:innen

DrugsEpidemiologyPublic Health

Substanzen

FentanylXylazineAnalgesics, OpioidHypnotics and Sedatives

Autor:innen und Institutionen

  • Virginia Commonwealth University, Richmond, Virginia, USA zhudt@vcu.edu.
  • Arizona State University, Tempe, Arizona, USA.

ORCID-Profile: David T Zhu

Zitieren

APA

Zhu, D. T., & Cano, M. (2025). Fentanyl-xylazine overdose deaths in the USA, 2018–2023. Injury Prevention. https://doi.org/10.1136/ip-2024-045596

Vancouver

Zhu DT, Cano M. Fentanyl-xylazine overdose deaths in the USA, 2018–2023. Injury Prevention. 2025. doi:10.1136/ip-2024-045596

BibTeX
@article{Zhu2025,
  author = {Zhu, David T and Cano, Manuel},
  title = {Fentanyl-xylazine overdose deaths in the USA, 2018–2023},
  journal = {Injury Prevention},
  year = {2025},
  doi = {10.1136/ip-2024-045596}
}
Kostenlos starten →